Drug Profile
XHA
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Virtici
- Class
- Mechanism of Action Immunomodulators; T lymphocyte modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Allergic-rhinitis in USA (Intranasal)
- 12 Aug 2016 Preclinical trials in Allergic rhinitis in USA (Intranasal)